I personally doubt that this latest news would make any big pharma sweat. They'd have companies like TIS coming to their offices every day asking for money. It's really just another deal to them, hence why they've low-balled TIS during round 1, treating it as they would any other negotiation.
The increase in capital by TIS certainly removes one of the wedges that the pharmas would've been using previously during the negotiations however they would still have many more up there sleeves and won't be afraid to use them. TIS for one has stated publicly that they can't afford to actually take this product to market alone and the pharmas would've quickly figured this out once discussions had begun.
Ultimately TIS is really just hoping to achieve the best possible terms for the deal (in terms of royalties) and it may just be in the end that they have to re-adjust their original expectations of what was achievable or continue pushing ahead of taking the product through the human trials and approvals process in order to increase the value proposition for the potential buyers.
Add to My Watchlist
What is My Watchlist?